MedPath

Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease

Phase 2
Completed
Conditions
Graft-versus-Host Disease
Registration Number
NCT00054613
Lead Sponsor
Mallinckrodt
Brief Summary

The purpose of this study is to determine whether extracorporeal photoimmune therapy with UVADEX (ECP) added to standard therapy is effective in the treatment of chronic graft-versus-host disease (GvHD).

Detailed Description

For patients who survive allogeneic bone marrow transplants greater than 100 days, chronic GvHD is a major cause of non-relapse morbidity and mortality. Depending on the presence of known associated risk factors, chronic GvHD will occur in 20-50% of these transplant recipients, with mortality rates varying from 20 to 70%.

Because a lymphocyte-mediated immune reaction is thought to be involved in GvHD, suppression of these cells by means other than medications could have benefit in the GvHD population.

ECP is a technique in which peripheral white blood cells are exposed to a photoactivatable compound (UVADEX) administered extracorporeally and ultraviolet A light. After cells are reinfused into the patient, their function is altered, thereby activating mechanisms that allow for further regulation of specific lymphocyte populations.

The purpose of this study is to determine whether ECP, in conjunction with standard therapy, is effective in the treatment of chronic GvHD. Efficacy of the therapy with respect to skin manifestations of the disease will be determined by a blinded skin assessor.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
72
Inclusion Criteria
  • Documented skin disease classical for chronic GvHD (e.g. hypopigmentation, hyperpigmentation, lichenoid lesions, sclerodermatous lesions)greater than or equal to 100 days post transplantation.
  • Patients with documented chronic GvHD that is corticosteroid refractory, corticosteroid dependent or corticosteroid intolerant.
  • Women of childbearing potential must agree to use a reliable method of birth control for the duration of this study.
  • Patients must weight at least 40 kg (88 lbs.)
Exclusion Criteria
  • Active gastrointestinal bleeding
  • Previous treatment with ECP
  • Females who are pregnant and/or lactating

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (31)

University of Florida

๐Ÿ‡บ๐Ÿ‡ธ

Gainesville, Florida, United States

University of Nebraska

๐Ÿ‡บ๐Ÿ‡ธ

Omaha, Nebraska, United States

Ankara University Medical School

๐Ÿ‡น๐Ÿ‡ท

AltฤฑndaฤŸ, Ankara, Turkey

General Hospital of Vienna

๐Ÿ‡ฆ๐Ÿ‡น

Vienna, Austria

University of Chicago

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

University of Arkansas for Medical Sciences

๐Ÿ‡บ๐Ÿ‡ธ

Little Rock, Arkansas, United States

Rush Presbyterian - St. Lukes Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Ludwig-Maximilians-Universitaet Muenchen

๐Ÿ‡ฉ๐Ÿ‡ช

Munchen, Germany

University of Michigan

๐Ÿ‡บ๐Ÿ‡ธ

Ann Arbor, Michigan, United States

Hopital Edouard Herriot

๐Ÿ‡ซ๐Ÿ‡ท

Lyon Cedex 03, France

Instituto Portugues de Oncologia de Francisco Gentil

๐Ÿ‡ต๐Ÿ‡น

Lisboa, Portugal

Klinika hematologie a transfuziologie FN

๐Ÿ‡ธ๐Ÿ‡ฐ

Bratislava, Slovakia

San Martino Hospital

๐Ÿ‡ฎ๐Ÿ‡น

Genova, Italy

Kantonsspital Basel

๐Ÿ‡จ๐Ÿ‡ญ

Basel, Switzerland

Hospital dela Santa Creu i Sant Pau. Universitat Autonoma de Barcelona

๐Ÿ‡ช๐Ÿ‡ธ

Barcelona, Spain

Tufts New England Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Kansas City Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Kansas City, Missouri, United States

Jewish Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Cincinnati, Ohio, United States

Brigham and Womens

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Fred Hutchinson Cancer Research Center

๐Ÿ‡บ๐Ÿ‡ธ

Seattle, Washington, United States

Peter MacCallum

๐Ÿ‡ฆ๐Ÿ‡บ

East Melbourne, Australia

Alfred Hospital

๐Ÿ‡ฆ๐Ÿ‡บ

Melbourne, Australia

Hopital Pitie-Salpetriere

๐Ÿ‡ซ๐Ÿ‡ท

Paris, France

Royal Melbourne Hospital

๐Ÿ‡ฆ๐Ÿ‡บ

Parkville, Australia

St. Vincent's Hospital

๐Ÿ‡ฆ๐Ÿ‡บ

Darlinghurst, New South Wales, Australia

Universitatis Hautklinik

๐Ÿ‡ฉ๐Ÿ‡ช

Essen, Germany

Careggi Hospital

๐Ÿ‡ฎ๐Ÿ‡น

Florence, Italy

University of Dresden

๐Ÿ‡ฉ๐Ÿ‡ช

Dresden, Germany

Universitatsklinikum Leipzig AOR

๐Ÿ‡ฉ๐Ÿ‡ช

Leipzig, Germany

Rotherham General Hospital

๐Ÿ‡ฌ๐Ÿ‡ง

Rotherham, Yorkshire, United Kingdom

Glasgow Royal Infirmary

๐Ÿ‡ฌ๐Ÿ‡ง

Glasgow, United Kingdom

ยฉ Copyright 2025. All Rights Reserved by MedPath